Equities research analysts predict that Xencor Inc (NASDAQ:XNCR) will report earnings per share of ($0.45) for the current quarter, according to Zacks Investment Research. Four analysts have issued estimates for Xencor’s earnings, with the highest EPS estimate coming in at ($0.33) and the lowest estimate coming in at ($0.58). Xencor posted earnings per share of ($0.46) in the same quarter last year, which suggests a positive year over year growth rate of 2.2%. The company is expected to announce its next quarterly earnings report on Monday, August 5th.
According to Zacks, analysts expect that Xencor will report full-year earnings of ($0.08) per share for the current fiscal year, with EPS estimates ranging from ($0.46) to $0.17. For the next year, analysts expect that the company will report earnings of ($1.84) per share, with EPS estimates ranging from ($2.84) to ($0.77). Zacks Investment Research’s earnings per share averages are an average based on a survey of research firms that follow Xencor.
Xencor (NASDAQ:XNCR) last announced its quarterly earnings results on Thursday, May 9th. The biopharmaceutical company reported $1.38 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of $0.43 by $0.95. The firm had revenue of $111.94 million for the quarter, compared to analysts’ expectations of $60.05 million.
Several equities research analysts have recently commented on the company. Cantor Fitzgerald reissued a “buy” rating and set a $40.00 price target on shares of Xencor in a research note on Sunday, May 12th. Zacks Investment Research lowered Xencor from a “buy” rating to a “hold” rating in a research note on Saturday, May 4th. Berenberg Bank assumed coverage on Xencor in a research note on Wednesday, March 27th. They set a “buy” rating and a $45.00 price target on the stock. BidaskClub raised Xencor from a “strong sell” rating to a “sell” rating in a research note on Tuesday, May 7th. Finally, Nomura lowered Xencor from a “neutral” rating to a “reduce” rating and decreased their price target for the stock from $28.00 to $21.00 in a research note on Friday, February 22nd. Two analysts have rated the stock with a sell rating, one has issued a hold rating and ten have given a buy rating to the stock. Xencor has an average rating of “Buy” and an average target price of $42.44.
In related news, major shareholder John S. Stafford III acquired 5,500 shares of the business’s stock in a transaction that occurred on Monday, March 25th. The stock was purchased at an average cost of $29.84 per share, for a total transaction of $164,120.00. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, major shareholder John S. Stafford III acquired 2,000 shares of the business’s stock in a transaction that occurred on Friday, March 22nd. The shares were bought at an average price of $29.96 per share, with a total value of $59,920.00. The disclosure for this purchase can be found here. Insiders have purchased a total of 35,852 shares of company stock valued at $1,070,947 over the last 90 days. Insiders own 4.70% of the company’s stock.
Several institutional investors have recently modified their holdings of XNCR. Shell Asset Management Co. acquired a new position in shares of Xencor during the 1st quarter worth approximately $145,000. Gotham Asset Management LLC acquired a new position in shares of Xencor during the 4th quarter worth approximately $240,000. Amalgamated Bank acquired a new position in shares of Xencor during the 4th quarter worth approximately $248,000. Spark Investment Management LLC acquired a new position in shares of Xencor during the 1st quarter worth approximately $312,000. Finally, Equitec Specialists LLC raised its position in shares of Xencor by 6.1% during the 1st quarter. Equitec Specialists LLC now owns 10,417 shares of the biopharmaceutical company’s stock worth $324,000 after purchasing an additional 600 shares during the last quarter. Hedge funds and other institutional investors own 83.51% of the company’s stock.
Shares of NASDAQ:XNCR opened at $32.49 on Tuesday. The company has a market cap of $1.77 billion, a PE ratio of -24.80 and a beta of 1.31. The company has a debt-to-equity ratio of 0.02, a quick ratio of 6.66 and a current ratio of 6.66. Xencor has a 12 month low of $27.75 and a 12 month high of $48.38.
Xencor, Inc, a clinical stage biopharmaceutical company, focuses on the discovery and development of engineered monoclonal antibody and other protein therapeutics to treat severe and life threatening diseases with unmet medical needs. It develops its antibody product candidates to treat autoimmune and allergic diseases, cancer, and other conditions.
Further Reading: How is the discount rate different from the Federal Funds rate?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Xencor Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Xencor and related companies with MarketBeat.com's FREE daily email newsletter.